GLP-1 medications
GLP-1 is a hormone your gut releases after you eat — it tells your brain you're full and helps your body manage blood sugar. GLP-1 medications (semaglutide, tirzepatide, and newer molecules) copy that signal, which is why they're so widely studied for weight management and metabolic health.
The articles below explain how these medications work, what the research actually shows, and what side effects and dosing schedules look like in practice. Promise offers compounded GLP-1 medications by prescription only: a licensed provider reviews every request, and not everyone qualifies.
308 articles on this topic
-

STEP 3 Trial Results: What the 16% Included
Average weight loss was 16.0% with semaglutide versus 5.7% with placebo. Both groups had intensive behavioral support, so the added difference matters.
-

Can You Take Antibiotics With Tirzepatide?
Amoxicillin and doxycycline are not named as tirzepatide interactions in their labels. Slower pill absorption and new diarrhea still need a separate check.
-

Why Is World Diabetes Day November 14?
November 14 honors Frederick Banting's birthday. The campaign began in 1991; UN recognition followed in 2006, with annual UN observance starting in 2007.
-

Cold Medicine With Semaglutide: Can They Mix?
Some adults can use a cold remedy during semaglutide treatment. The ingredients, other prescriptions, and ability to keep fluids down decide the answer.
-

CAMEO-SEMA Trial: Lower Heart-Filling Pressure
A small semaglutide trial found lower heart-filling pressure during exercise. Its remission result describes pressure tests, not freedom from heart failure.
-

FDA GLP-1 Vision Warning: Label Changes Required
FDA now requires a warning about rare optic-nerve injury across GLP-1 medicines. Here are the reported rates, urgent symptoms and treatment questions.
-

Foundayo Sleep Apnea: Fewer Breathing Pauses
Foundayo reduced breathing interruptions in two year-long trials. The pill is not authorized to treat sleep apnea, and airway treatment still needs reassessment.
-

Hims Zepbound Deal Adds a Route to Lilly’s Brands
The November 6 agreement concerns branded Zepbound and Foundayo. It changes the access route while leaving the prescription decision with the clinician and patient.
-

Semaglutide Gene Study: A Clue to Slow Weight Loss
A new study linked rare gene changes to less weight loss on semaglutide. The finding concerns a tiny group and doesn't make genetic testing routine.
-

Stopping GLP-1 Heart Risk: What Higher Rates Mean
A new study links stopping GLP-1 treatment with more heart attacks, strokes or deaths in people with type 2 diabetes. The reasons people stopped may explain part of the difference.
-

Tirzepatide Resistance Training: Strength Rose
A new 120-person trial found better strength and less loss of tissue that includes muscle, organs and water. Training did not prevent all loss.
-

Tirzepatide vs Semaglutide Muscle Loss: No Winner
A new health-record study links greater lean-mass loss on tirzepatide to greater weight loss. It does not establish which medicine better protects muscle.
-

SUSTAIN 7 Trial Results: Blood Sugar and Weight
Semaglutide had larger blood-sugar and weight changes in this 40-week diabetes trial. The four study doses and who took part set the limits of that finding.
-

Saxenda Prescribing Information, in Plain English
Saxenda is a daily liraglutide medicine for weight management. Its label has different dose checks for adults and teenagers, plus warnings that matter at any age.
-

WOMAC Score Meaning: What the Numbers Tell You
WOMAC tracks arthritis pain, stiffness and daily movement. Its scale matters: a score change describes symptoms, and doesn't prove joint repair.
-

When Was Zepbound Approved? November 8, 2023
Zepbound’s weight-management approval dates to November 8, 2023. Its later sleep-apnea use, devices, label changes, and Medicare access each have their own timeline.
-

GLP-1 Prior Authorization Denied? What Comes Next
The denial reason decides the next step: missing records, an unmet coverage rule, or an excluded benefit. An appeal needs to address that specific issue.
-

Acmopatide Type 1 Diabetes: Small Blood Sugar Drop
A 111-person trial found weight loss and a small blood sugar change alongside insulin. Roche had already announced that development would stop.
-

GLP-1 Liver Cancer Study: Prevention Is Unproven
A new study found lower liver-cancer rates in people with diabetes and viral hepatitis. It doesn't prove prevention or apply to every GLP-1 user.
-

Does Semaglutide Cause Bone Loss? What We Know
Bone density can fall during semaglutide-related weight loss. New reviews and the Wegovy label explain why fracture risk needs a more individual answer.
Page 1 of 16 · 308 articles